PREMIA and Lind Launch Lind Asia to Revolutionize Clinical Trials with AI

Key Takeaways

• Precision Medicine Asia (PREMIA) and Lind announced Lind Asia on 27 May 2026 as a strategic joint venture for AI-powered clinical-trial enrollment in Asia-Pacific.
• Lind Asia is the exclusive regional partner for Lind’s screening platform, localized first for Taiwan, Japan, South Korea, Singapore, and Australia.
• The platform’s three pillars are AI patient identification from EHR data, a research-ready site network, and integrated genomic/proteomic profiling for biomarker matching.
• Leadership planned partnering meetings at the ASCO Annual Meeting in Chicago from 29 May to 2 June 2026.

What did PREMIA and Lind announce?

On 27 May 2026, Precision Medicine Asia, Limited (PREMIA) and Lind announced the formation of Lind Asia, a strategic joint venture focused on clinical-trial enrollment across Asia-Pacific.

The GlobeNewswire release states that Lind Asia will serve as the exclusive regional partner for Lind’s AI-powered screening platform by leveraging PREMIA’s expertise in managing clinical-genomic databases to accelerate patient eligibility screening.

PREMIA, established in 2018, describes itself as an Asia-focused clinical-genomic data management platform provider working with regional hospitals. Company information is available on the PREMIA corporate site, which also points partners to Lind Asia at lindasia.care.

Lind describes itself as a precision trial-matching platform designed to work at the point of care with electronic health-record integration and HIPAA-compliant data access; more detail is published at lind.care.

How will Lind Asia’s AI screening platform work?

According to the joint announcement, Lind Asia’s platform is built around three pillars.

First, AI-powered patient identification analyzes structured and unstructured EHR data to surface potentially eligible patients for clinical trials. That addresses a common bottleneck where inclusion and exclusion criteria are buried across notes, labs, and imaging reports rather than in clean structured fields.

Second, a research-ready site network aims to connect partner health systems so multinational sponsors can enroll across multiple Asia-Pacific markets through a more coordinated screening workflow.

Third, integrated molecular profiling incorporates genomic and proteomic data to support biomarker-driven trial matching and targeted-therapy development—aligned with PREMIA’s historical focus on clinical-genomic databases.

Wenn Sun, Founder and Managing Partner of PREMIA, said the venture combines PREMIA’s regional infrastructure with Lind’s AI platform to improve recruitment efficiency, reduce screen failures, and expedite access to innovative therapies. Oggie Nikolic, Chief Executive Officer of Lind, framed Lind Asia as a step toward evidence-driven screening for health systems and sponsors globally.

Which Asia-Pacific markets are in scope?

The companies said Lind’s platform will be localized for healthcare institutions across Taiwan, Japan, South Korea, Singapore, and Australia. Localization matters because language, privacy rules, EHR vendors, and consent frameworks differ sharply across those markets even when protocols are multinational.

For sponsors, the practical question is whether Lind Asia can shorten the time from site activation to first patient screened without increasing screen-failure rates—especially in biomarker-defined oncology studies where genomic eligibility is the rate limiter.

The Asia-Pacific trial-services backdrop continues to expand; NovaPharmaNews has separately covered the clinical trials outsourcing market outlook for 2026–2034 and the broader shift toward AI-enabled capital-efficient biotech development.

Why does AI trial matching matter for sponsors and sites?

Patient identification remains one of the slowest and most expensive phases of interventional research. Manual chart review does not scale when protocols require complex biomarker, prior-therapy, and comorbidity logic.

An AI layer that can read unstructured notes and link to molecular profiles is most valuable when sites already capture high-quality genomic data—PREMIA’s stated specialty—and when sponsors are running multi-country Asia-Pacific cohorts rather than single-country pilots.

Buyers should still demand validation evidence: sensitivity and specificity versus manual screening, screen-failure reduction, time-to-identify metrics, and data-governance documentation under local privacy regimes. The announcement does not publish those performance numbers, so BD and clinical-operations teams should treat the release as a go-to-market signal, not a completed efficacy claim.

Oncology imaging and immunotherapy growth in markets such as Australia also increases demand for better trial funnel management; see related coverage of immunotherapy-driven PET/CT demand in Australia.

What is next for partnering and visibility?

Lind and Lind Asia leadership said they would attend the American Society of Clinical Oncology Annual Meeting in Chicago from 29 May to 2 June 2026 to discuss recruitment timelines with potential partners. Meeting logistics and scientific program context are published by ASCO.

Partnering inquiries were directed to [email protected]. Sponsors evaluating the offering should ask for country-by-country deployment timelines, EHR integration list, genomic data sources, and any existing site contracts in the five named markets.

Until those details are public, the clearest facts remain the JV structure, exclusive regional-partner status, five-market localization plan, three platform pillars, and ASCO partnering window—all stated in the 27 May 2026 company announcement.

Frequently Asked Questions

Primary Sources

• GlobeNewswire — PREMIA and Lind Form Lind Asia (27 May 2026)
• Precision Medicine Asia (PREMIA) — corporate site
• Lind — precision trial-matching platform
• American Society of Clinical Oncology — Annual Meeting